DOACs vs. Warfarin After TAVR: Insights From the STS/ACC TVT Registry – American College of Cardiology
Use of direct oral anticoagulants (DOACs) as opposed to warfarin after TAVR exhibited a lower risk of bleeding requiring hospitalization, all-cause mortality and stroke at one-year, according to a recent study published in American Heart Journal. Using data from the STS/ACC TVT Registry linked with claims data from the Centers for Medicare and Medicaid Services, Tomo Ando, MD, et al., incorporated 29,142 patients who underwent TAVR between January 2013 and May 2018 and were discharged on an oral anticoagul